Carlo Visco

10.7k total citations · 1 hit paper
108 papers, 2.4k citations indexed

About

Carlo Visco is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Carlo Visco has authored 108 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pathology and Forensic Medicine, 54 papers in Genetics and 49 papers in Oncology. Recurrent topics in Carlo Visco's work include Lymphoma Diagnosis and Treatment (67 papers), Chronic Lymphocytic Leukemia Research (53 papers) and Viral-associated cancers and disorders (25 papers). Carlo Visco is often cited by papers focused on Lymphoma Diagnosis and Treatment (67 papers), Chronic Lymphocytic Leukemia Research (53 papers) and Viral-associated cancers and disorders (25 papers). Carlo Visco collaborates with scholars based in Italy, United States and Spain. Carlo Visco's co-authors include Francesco Rodeghiero, Ken H. Young, Zijun Y. Xu‐Monette, Michael Møller, Attilio Orazi, Ronald S. Go, Mikael Frederiksen, Ole Nielsen, Torben Mourits‐Andersen and Lars Møller Pedersen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Carlo Visco

104 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

2012 481 citations Ken H. Young, Carlo Visco et al. Journal of Clinical Oncology profile →

Peers

Carlo Visco

PFM

GENET

ONCOL

IMMUN

Achiel Van Hoof Belgium

Loïc Ysebaert France

Diying Shen China

Meyer R. Heyman United States

Isabelle Bence‐Bruckler Canada

C. Varns United States

Enrico Derenzini Italy

Santiago Montes‐Moreno Spain

Alejandro Martı́n Spain

Mathias Witzens‐Harig Germany

Achiel Van Hoof Belgium

Carlo Visco

1.9k ×1.3

PFM

918 ×0.8

GENET

1.3k ×1.3

ONCOL

339 ×0.8

IMMUN

375 ×1.0

Citations per year, relative to Carlo Visco Carlo Visco (= 1×) peers Achiel Van Hoof

Countries citing papers authored by Carlo Visco

Since Specialization

Citations

This map shows the geographic impact of Carlo Visco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Visco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Visco more than expected).

Fields of papers citing papers by Carlo Visco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Visco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Visco. The network helps show where Carlo Visco may publish in the future.

Co-authorship network of co-authors of Carlo Visco

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Visco. A scholar is included among the top collaborators of Carlo Visco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Visco. Carlo Visco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Galasso, Marilisa, Riccardo Moia, Chiara Cosentino, et al.. (2024). CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia. Hematological Oncology. 42(6). e70002–e70002.

Quaglia, Francesca Maria, et al.. (2024). Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin’s Lymphoma: A Case Report and Review of the Literature. Journal of Clinical Medicine. 13(19). 5756–5756.

Visco, Carlo. (2023). Letting the mantle out of the bag. British Journal of Haematology. 204(1). 11–13.

Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585. 11 indexed citations

Chung, Elaine Y., Giulio Sartori, Maurilio Ponzoni, et al.. (2023). ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells. British Journal of Haematology. 203(2). 244–254. 2 indexed citations

Lombardi, Guerino, Anna Maria Cantoni, A. Corradi, et al.. (2023). MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia. Leukemia. 37(8). 1671–1685. 1 indexed citations

Bailly, Sarah, Guillaume Cartron, Sridhar Chaganti, et al.. (2022). Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper. Hematological Oncology. 40(4). 505–517. 10 indexed citations

Olivieri, Jacopo, Rossella Paolini, Silvia Finotto, et al.. (2021). Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. Cancers. 13(23). 6089–6089. 8 indexed citations

Visco, Carlo, Francesca Pregnolato, Isacco Ferrarini, et al.. (2021). Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. Critical Reviews in Oncology/Hematology. 163. 103377–103377. 12 indexed citations

10.

Cappuzzello, Elisa, Andrea Visentin, Giuseppe Astori, et al.. (2021). Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. Journal for ImmunoTherapy of Cancer. 9(7). e002475–e002475. 11 indexed citations

11.

Merli, Michele, Irene Defrancesco, Carlo Visco, et al.. (2020). Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leukemia & lymphoma. 61(9). 2122–2128. 13 indexed citations

12.

Visco, Carlo, et al.. (2020). Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. Cancers. 12(10). 2913–2913. 29 indexed citations

13.

Kamga, Paul Takam, Riccardo Bazzoni, Francesca Maria Quaglia, et al.. (2019). Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia. Cancers. 11(12). 1958–1958. 23 indexed citations

14.

McCulloch, Rory, Carlo Visco, Rebecca Frewin, et al.. (2019). R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy. Blood. 134(Supplement_1). 3989–3989. 4 indexed citations

15.

Santi, Roberto, Manuela Ceccarelli, Chiara Monagheddu, et al.. (2016). A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). Annals of Oncology. 27. vi316–vi316. 1 indexed citations

16.

Frei, Emil, Carlo Visco, Zijun Y. Xu‐Monette, et al.. (2013). Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Journal of Clinical Pathology. 66(11). 956–961. 19 indexed citations

17.

Visco, Carlo, Silvia Finotto, Renato Zambello, et al.. (2013). Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology. 31(11). 1442–1449. 126 indexed citations

18.

Visco, Carlo, Agostino Cortelezzi, Francesca Moretta, et al.. (2013). Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?. Leukemia & lymphoma. 55(6). 1261–1265. 12 indexed citations

19.

Visco, Carlo, Francesco Maura, Giacomo Tuana, et al.. (2012). Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors. Clinical Cancer Research. 18(7). 1870–1878. 20 indexed citations

20.

Christie, David, Elías Gracia, M. Gospodarowicz, et al.. (2007). Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group. Haematologica. 92. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact